Pirtobrutinib in covalent BTK-inhibitor pre- treated relapsed/refractory (R/R) Mantle Cell Lymphoma

被引：0
|
作者：
Fileni, Caroline [1 ]
Sarkozy, Clementine [2 ]
机构：
[1] Hop Archet 1, Serv Hematol, Nice, France
[2] Inst Curie St Cloud, Serv Hematol, St Cloud, France
来源：
BULLETIN DU CANCER | 2023年 / 110卷 / 10期
关键词：
Mantle cell lymphoma; Relapse; Refractory; Covalent BTK-inhibitor; Non covalent BTK-inhibitor;
D O I：
10.1016/j.bulcan.2023.07.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：988 / 990
页数：3
相关论文
共 50 条
  • [31] First UK experience of BTK inhibitor PCI-32765-dramatic responses in relapsed/refractory mantle cell lymphoma
    Furtado, M. V.
    Rule, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 47 - 48
  • [32] Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor
    Salles, Gilles
    Chen, Jenny M. H.
    Zhang, Ina
    Kerbauy, Fabio
    Wu, James J.
    Wade, Sally W.
    Nunes, Ana
    Feng, Chaoling
    Kloos, Ioana
    Peng, Weimin
    Snider, Julia T.
    Maciel, Dylan
    Chan, Keith
    Keeping, Sam
    Shah, Bijal
    ADVANCES IN THERAPY, 2024, 41 (05) : 1938 - 1952
  • [33] Matching-adjusted indirect comparison of pirtobrutinib vs. venetoclax continuous monotherapy in patients with relapsed/refractory CLL previously treated with a covalent BTK inhibitor
    Davids, Matthew
    Al-Sawaf, Othman
    Jen, Min-Hua
    Hess, Lisa M.
    Zhang, Jiewen
    Goebel, Benjamin
    Pagel, John M.
    Eyre, Toby A.
    LEUKEMIA & LYMPHOMA, 2023, 64 : S78 - S79
  • [34] Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor
    Gilles Salles
    Jenny M. H. Chen
    Ina Zhang
    Fabio Kerbauy
    James J. Wu
    Sally W. Wade
    Ana Nunes
    Chaoling Feng
    Ioana Kloos
    Weimin Peng
    Julia T. Snider
    Dylan Maciel
    Keith Chan
    Sam Keeping
    Bijal Shah
    Advances in Therapy, 2024, 41 : 1938 - 1952
  • [35] BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma
    Eyre, Toby A.
    Shah, Nirav N.
    Dreyling, Martin
    Jurczak, Wojciech
    Wang, Yucai
    Cheah, Chan Y.
    Song, Yuqin
    Gandhi, Mitul
    Chay, Christopher
    Sharman, Jeff
    Andorsky, David J.
    Messersmith, Hannah M.
    Ruppert, Amy S.
    Muthig, Valerie A.
    Ito, Rodrigo
    Wang, Michael L.
    FUTURE ONCOLOGY, 2022, 18 (36) : 3961 - 3969
  • [36] Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis
    J. Wu, James
    Wade, Sally W.
    Itani, Taha
    Castaigne, Jean-Gabriel
    Kloos, Ioana
    Peng, Weimin
    Kanters, Steve
    Zoratti, Michael J.
    Dreyling, Martin
    Shah, Bijal
    Wang, Michael
    LEUKEMIA & LYMPHOMA, 2024, 65 (11) : 1609 - 1622
  • [37] Pirtobrutinib, A Next Generation, Highly Selective, Non-covalent BTK Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 BRUIN Study
    Shah, Nirav N.
    Alencar, Alvaro J.
    Gerson, James N.
    Patel, Manish R.
    Fakhri, Bita
    Jurczak, Wojciech
    Tan, Xuan
    Lewis, Katharine
    Fenske, Timothy
    Coombs, Catherine C.
    Flinn, Ian
    Lewis, David
    Le Gouill, Steven
    Palomba, M. Lia
    Woyach, Jennifer
    Pagel, John M.
    Lamanna, Nicole
    Cohen, Johnathon B.
    Barve, Minal A.
    Ghia, Paolo
    Eyre, Toby A.
    Mato, Anthony R.
    Cheah, Chan Y.
    Wang, Michael L.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 170 - 171
  • [38] Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study
    Wang, Michael
    Shah, Nirav N.
    Alencar, Alvaro J.
    Gerson, James N.
    Patel, Manish R.
    Fakhri, Bita
    Jurczak, Wojciech
    Tan, Xuan Ni
    Lewis, Katharine
    Fenske, Timothy S.
    Coombs, Catherine C.
    Flinn, Ian W.
    Lewis, Davi John
    Le Gouill, Steven
    Palomba, M. Lia
    Woyach, Jennifer A.
    Pagel, John M.
    Lamanna, Nicole
    Cohen, Jonathon B.
    Barve, Minal A.
    Ghia, Paolo
    Eyre, Toby A.
    Zinzani, Pier Luigi Luigi
    Ujjani, Chaitra S.
    Koh, Youngil
    Izutsu, Koji
    Lech-Maranda, Ewa
    Tam, Constantine S.
    Sundaram, Suchitra
    Yin, Ming
    Nair, Binoj
    Balbas, Minna
    Tsai, Donald
    Mato, Anthony R.
    Cheah, Chan Yoon
    BLOOD, 2021, 138
  • [39] Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
    Shah, Bijal
    Challagulla, Swetha
    Xu, Sheng
    Williams, Rhys
    Ren, Shijie
    Srivastava, Tushar
    Gautam, Raju
    Yang, Keri
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S516 - S517
  • [40] Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study
    Patel, Krish
    Vose, Julie M.
    Nasta, Sunita D.
    Brown, Jennifer R.
    Maddocks, Kami J.
    Woyach, Jennifer A.
    Shah, Nirav N.
    Fakhri, Bita
    Tessoulin, Benoit
    Ma, Shuo
    Jagadeesh, Deepa
    Lech-Maranda, Ewa
    Coombs, Catherine C.
    Patel, Manish
    Rhodes, Joanna M.
    Ujjani, Chaitra S.
    Hoffmann, Marc S.
    Cheah, Chan Y.
    Munir, Talha
    Lewis, David
    Scarfo, Lydia
    Eyre, Toby A.
    Alencar, Alvaro J.
    Cohen, Jonathon B.
    Zelenetz, Andrew D.
    Tsai, Donald E.
    Li, Mei
    Bian, Faith
    Abada, Paolo
    Zinzani, Pier Luigi
    BLOOD, 2023, 142
12345